Duloxetine Capsule, Delayed Release
Product Images NDC 70518-3287

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-3287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

DULoxetine is a delayed-release capsule containing 30mg of medication. The bottle contains 60 capsules and can be identified with NDC #: 70518-3287-00. It was manufactured by Ajanta Pharma Ltd. in Paithan, India with the source NDC: 27241-0098-10. Specific storage directions are provided, stating to keep it between 20-26°C (63-77°F), with permitted excursions to 15-30°C (59-86°F) [See USP]. The package insert contains instructions for use, and the medication must be kept away from children. It was repackaged by RemedyRepack Inc. in Indiana, PA. However, the expiration date and lot number are not available.*

FDA Label Image

Figure1 (Duloxetine Fig1)

This data appears to be a chart showing the number of patients who experienced a relapse during a study of a placebo group versus a group taking a medication called Duloxetine. The x-axis shows the time from randomization to relapse in days, and the y-axis shows the number of patients. The chart suggests that Duloxetine may be more effective at preventing relapse than the placebo, based on the lower number of patients experiencing relapse in the Duloxetine group compared to the placebo group at various time points.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This text describes a medication called "Duloxetine" in doses of 60/120 mg once a day as a treatment for pain. The text also includes a graph showing the percentage improvement in pain from the baseline.*

FDA Label Image

Figure2 (Duloxetine Fig2)

The graph shows the proportion of patients who experienced relapse over time after randomization to either placebo or Duloxetine treatment in days. It appears that patients on Duloxetine had a lower proportion of relapses compared to those on placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

The text contains a table displaying the percentage of patients improved for different doses of Duloxetine and Placebo. The table also includes information on the percentage improvement in pain from baseline.*

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

This appears to be a chart showing the percentage of patients who improved with different treatment options for pain. The chart compares the effectiveness of Dulozetine (at different dosages) and a Placabo. The percentage of patients who experienced improvement in pain from baseline is also displayed.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure8 (Duloxetine Fig8)

This is a report on the use of Duloxetine at doses of 60/120mg once daily as a placebo. The text includes a numerical table with percent improvement in pain from baseline. The remaining text seems to be non-sensical and unclear.*

FDA Label Image

Figure9 (Duloxetine Fig9)

The text describes a clinical trial involving the use of a placebo and a once-daily dose of Duloxetine 60 mg for pain relief. The trial measured the percent improvement in pain from baseline using BOCF (Baseline Observation Carried Forward) method. However, there is some garbled text and symbols that are not understandable.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.